Circulating Thrombomodulin as a Molecular Marker of Endothelium Damage in Renal Transplant Recipients
Author(s) -
İbrahim C. Haznedaroğlu,
Yurdagül Erdem,
Ahmet Uğur Yalçın,
Nilgün Sayınalp,
Ünal Yasavul,
Çetin Turgan,
S Cağlar,
Sebahat Altundağ Dündar,
S Kirazli
Publication year - 1996
Publication title -
the nephron journals/nephron journals
Language(s) - English
Resource type - Journals
eISSN - 2235-3186
pISSN - 1660-8151
DOI - 10.1159/000189118
Subject(s) - medicine , thrombomodulin , nephrology , endothelium , renal transplant , transplantation , pathology , cardiology , platelet , thrombin
Dr. İbrahim C. Haznedaroğlu, 36. sok. Sun apt. No: 3/2, 06490, Bahçelievler, TR-06490 Ankara (Turkey) Dear Sir, Thrombomodulin (TM) is a cell surface glycoprotein located at the luminal surface of vascular endothelium as a membrane-bound high-affinity thrombin receptor [1], It inactivates thrombin and stimulates anticoagula-tory pathways. TM therefore belong to the anticoagulant defence system against thrombosis and plays a crucial role in the regulation of blood coagulation and fibrinolysis in vivo [2]. Consequently, quantitative and/or qualitative impairment of TM could possibly play a pathogenetic role in the thrombo-genesis and endothelial damage [3]. A smaller soluble form of TM has been isolated from human blood and urine [4]. The structure of soluble TM is not known but is thought to be similar to the soluble protein obtained after proteolytic modification of TM with elastase [5], a cleaved form of tissue TM with loss of part of the trans-membrane domain and the cytoplasmatic tail [6]. Therefore soluble TM, which exists in circulating plasma as heterogenous fragments, appears to be derived from injured endothelial cells or to be proteolytically cleaved from TM by proteases [7]. Soluble TM is cleared from the circulation by the kidneys and liver [2]. The study was a cross-sectional determination of TM, a major component on the endothelial surface, concentrations in plasma from renal transplant recipients and healthy volunteers. Seventeen renal transplant recipients with normal graft function (serum creatinine < 2 mg/dl; 8 females, 9 males, age 31 ± 2 years, mean transplantation duration 34 ± 6 months), 7 renal transplant recipients in chronic rejection (serum creatinine > 2 mg/dl; 2 females, 5 males, age 39 ± 3 years, mean transplantation duration 44 ± 11 months) and 15 nonsmoking healthy volunteers (7 females, 8 males, age 26 ± 9 years) with normal renal function were included in the study. Patients selected for this study were on triple
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom